Body weight at age 20 and in midlife is more important than weight gain for coronary atherosclerosis: Results from SCAPIS.

Background and Aims: Elevated body weight in adolescence is associated with early cardiovascular disease, but whether this association is traceable to weight in early adulthood, weight in midlife or to weight gain is not known. The aim of this study is to assess the risk of midlife coronary atherosclerosis being associated with body weight at age 20, body weight in midlife and body weight change.
Methods: We used data from 25,181 participants with no previous myocardial infarction or cardiac procedure in the Swedish CArdioPulmonary bioImage Study (SCAPIS, mean age 57 years, 51% women). Data on coronary atherosclerosis, self-reported body weight at age 20 and measured midlife weight were recorded together with potential confounders and mediators. Coronary atherosclerosis was assessed using coronary computed tomography angiography (CCTA) and expressed as segment involvement score (SIS).
Results: The probability of having coronary atherosclerosis was markedly higher with increasing weight at age 20 and with mid-life weight (p < 0.001 for both sexes). However, weight increase from age 20 until mid-life was only modestly associated with coronary atherosclerosis. The association between weight gain and coronary atherosclerosis was mainly seen in men. However, no significant sex difference could be detected when adjusting for the 10-year delay in disease development in women.
Conclusions: Similar in men and women, weight at age 20 and weight in midlife are strongly related to coronary atherosclerosis while weight increase from age 20 until midlife is only modestly related to coronary atherosclerosis.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: GB reports grants for the present work from the Swedish Research Council, the Swedish Heart Lung foundation and from local government funds in Gothenburg, Sweden. EH reports research grant funding from Sanofi-Aventis, Pfizer, Amgen, Swedish Heart Lung foundation, and consulting or honoraria from Amgen, Sanofi-Aventis, Novartis, Amarin, and NovoNordisk. AR reports grants from AFA Insurance and the Swedish Research Council (2018–02527). EL reports consulting fees from Biogen outside of this work. JS repots being a shareholder in Anagram kommunikation AB and Symptoms Europe AB outside of this work. SKJ reports research grants to the institution from AstraZeneca, Bayer, Jansen, Novartis, Amgen outside of this work. SKJ reports participation on Data Safety Monitoring Board or Advisory Board for New Holland, the Obecetrapid study outside of this work. SS reports speaker's honoraria from Actelion/Johnson&Johnson outside of this work. SS reports being co-chair at the PAH forum in Madrid 2022 outside of this work. SS being part of advisory boards for Actelion/Johnson&Johnson and Novarits outside of this work. The rest of the authors declare no competing financial interest or conflicts of interest.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)